Search results
Results From The WOW.Com Content Network
RNA therapeutics are a new class of medications based on ribonucleic acid (RNA). Research has been working on clinical use since the 1990s, with significant success in cancer therapy in the early 2010s. [1] In 2020 and 2021, mRNA vaccines have been developed globally for use in combating the coronavirus disease (COVID-19 pandemic). [2]
Recent discoveries implicating RNA in the pathogenesis of several forms of cancer and neuromuscular diseases have created a paradigm shift in drug discovery.This work combined with advances in structural characterization techniques such as NMR spectroscopy, X-ray crystallography, Cryogenic electron microscopy [1] together with computational modeling, [2] has pushed forward the realization that ...
There are many additional therapeutics that have been developed and are either in phase I or II of the clinical trials. Current RNA therapeutics in clinical trials range from a variety of target organs and diseases ranging from skin (potential treatment for disease such as keloid) to tumors (squamous cell lung cancer).
New York, USA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- 80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight. With over 80 key companies active in the RNA therapies space, the market is projected to grow due to advancements in mRNA, siRNA, and antisense oligonucleotide-based therapies.
Antisense therapy is a form of treatment that uses antisense oligonucleotides (ASOs) to target messenger RNA (mRNA). ASOs are capable of altering mRNA expression through a variety of mechanisms, including ribonuclease H mediated decay of the pre-mRNA, direct steric blockage, and exon content modulation through splicing site binding on pre-mRNA. [1]
In clinic, Phase 1 Licensed to GSK: ARO-C3 Complement Mediated Disease In clinic, Phase 1 ARO-MUC5AC Muco-obstructive In clinic, Phase 1 ARO-RAGE Inflammatory In clinic, Phase 1 ARO-MMP7 Idiopathic Pulmonary Fibrosis: In clinic, Phase 1 ARO-COV Covid-19: Preclinical ARO-DUX4 FSHD: Preclinical HZN-457 Gout: In clinic, Phase 1 Partnered with Horizon
RNA Therapeutics Market Size is expected to reach US$ 948 Million by 2031, Report by CoherentMI 09/09/2024 11:10 -0400 Burlingame, Sept. 09, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, RNA Therapeutics Market is estimated to value at US$ 2.5 Million in the year 2024 and is anticipated to reach US$ 948 Million by 2031 , at a ...
Sirna Therapeutics, Inc. was a San Francisco, California based biotechnology company that explored the use of RNA interference in human disease therapy. Sirna's development pipeline included several small interfering RNA (siRNA) drugs , thought to stably silence the expression of specific disease-related genes.